公开(公告)号：US11583573B2

公开(公告)日：2023-02-21

申请号：US16710521

申请日：2019-12-11

申请人： Omrix Biopharmaceuticals Ltd.

发明人： Inbar Gahali-Sass ,  Israel Nur ,  Erez Ilan ,  Ronen Eavri

IPC分类号： A61K38/46 ,  A61K38/36 ,  A61K38/48 ,  A61P41/00 ,  A61K38/37 ,  A61K9/08 ,  A61P7/04 ,  A61K33/06 ,  A61K38/38

摘要： Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 μM to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 μM to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.

公开(公告)号：US11918629B2

公开(公告)日：2024-03-05

申请号：US16710541

申请日：2019-12-11

申请人： Omrix Biopharmaceuticals Ltd.

发明人： Israel Nur ,  Elena Grimberg ,  Itai Podoler ,  Inbar Gahali-Sass ,  Erez Ilan ,  Ronen Eavri

IPC分类号： A61K38/00 ,  A61K9/08 ,  A61K33/06 ,  A61K38/36 ,  A61K38/37 ,  A61K38/38 ,  A61K38/48 ,  A61P7/04 ,  A61P41/00

CPC分类号： A61K38/363 ,  A61K9/08 ,  A61K33/06 ,  A61K38/366 ,  A61K38/37 ,  A61K38/38 ,  A61K38/4833 ,  A61P7/04 ,  A61P41/00 ,  C12Y304/21005

摘要： Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.